In the frame of targeted therapies, future prospective controlled clinical trials should explore the use of cyclin-dependent kinase inhibitors (CDKIs) [56,57,58] in CDKN2A/2B-affected ALL pediatric subgroups. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.